With over 25 years of experience in the biotech industry and education from Columbia (Venture Capital and Private Equity Executive Program), MIT Sloan (MBA), and Boston College (Bachelor in Chemistry and Pre-med), Rozanna Yaing continues to elevate solutions that impact others and aspires to drive meaningful innovation by optimizing industry investments.
Yaing’s renowned expertise in quality, operation, and compliance has contributed to billion-dollar investments, and several startups, and secured her as a biotech changemaker, as evidenced by some of the best outcomes within the industry.
Yaing’s ability to maximize possibilities allows her to quickly identify challenges, gaps, and opportunities. Her experience is vast, ranging from critical organizations like Finch Therapeutics, Genzyme, Shire HGT, and Boston Scientific, just to name a few. Yaing’s leadership has powered organizations forward to achieve key strategic milestones and financial gains.
Throughout her impactful career, Yaing has played a crucial role in the development, scale-up, and commercialization of products. She has accelerated indication-specific drug product formulations, redefining microbiome manufacturing processes and gaining FDA approval for over six drugs. Additionally, she has conscientiously led diverse teams and driven strategic tech solutions for immune-oncology clinical trials.
Yaing’s highly-effective, multidimensional expertise and insight are invaluable when considering the evolution of the biotech industry. It is her unique ability to challenge organizations to think boldly when driving human solutions and global advancement while also ensuring a humanistic approach that keeps people at the center of all she does.
And, as a courageous Cambodian refugee and proud single mother of two, Yaing aims to fearlessly champion gender and racial equality and blaze the trail for others in the field and beyond.
